PET Study of Breast Cancer Patients Using [68Ga]ABY-025
关键词
抽象
描述
Open-labeled, exploratory, single center study.
1. Group 1 (dose-finding) Six subjects with HER2-positive primary tumor status and four subjects with HER2-negative status. [68Ga]ABY-025 PET with low dose (100 μg) of ABY-025 peptide is performed, followed by a repeated PET within three weeks using high dose (500 μg) ABY-025 peptide (radioactivity maximum 500 MBq). A third [68Ga]ABY-025 PET will be performed in the HER2-positive subgroup only, when signs of progressive disease are found at routine clinical evaluation or else latest after 12 months regardless of disease status, then using the ABY-025 peptide dose previously determined to be preferable.
2. Group 2 Ten subjects with HER2-positive primary tumor status. [68Ga]ABY-025 PET is performed using the ABY-025 peptide dose determined to be preferable during the dose-finding part of the study, followed by a second [68Ga]ABY-025 PET investigation at signs of progressive disease or else latest after 9 months.
日期
| 最后验证: | 12/31/2014 |
| 首次提交: | 04/11/2013 |
| 提交的预估入学人数: | 05/15/2013 |
| 首次发布: | 05/20/2013 |
| 上次提交的更新: | 01/11/2015 |
| 最近更新发布: | 01/12/2015 |
| 实际学习开始日期: | 03/31/2013 |
| 预计主要完成日期: | 05/31/2014 |
| 预计完成日期: | 05/31/2014 |
状况或疾病
干预/治疗
Drug: [68Ga]ABY-025
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: [68Ga]ABY-025 | Drug: [68Ga]ABY-025 Intravenous injection followed by PET imaging |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: 1. Subject is > 18 years of age 2. Diagnosis of invasive breast cancer with metastases 3. Availability of results from HER2 status previously determined on material from the primary tumor, either 1. HER2-positive, defined as a DAKO HercepTest™ score of 3+ or FISH positive or 2. HER2-negative, defined as a DAKO HercepTest™ score of 0 or 1+ or else; if 2+ then FISH negative 4. Volumetrically quantifiable metastasis lesions on CT or MRI, with at least one lesion >= 10 mm in smallest diameter and suitable for biopsy 5. ECOG performance status of =< 2 6. Life expectancy of at least 12 weeks 7. Hematological, liver and renal function test results within the following limits: White blood cell count: > 2.0 x 10^9/L Haemoglobin: > 80 g/L Platelets: > 50.0 x 10^9/L ALT, ALP, AST: =< 5.0 times Upper Limit of Normal Bilirubin =< 2.0 times Upper Limit of Normal Serum creatinine: Within Normal Limits or else normal clearance 8. A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all female patients of childbearing potential, who must use a medically acceptable form of contraception from study start until at least 30 days after study termination 9. Subject is able to participate in the diagnostic investigations to be performed in the study 10. Informed consent Exclusion Criteria: 1. Manifest second, non-breast malignancy 2. Known HIV positive or chronically active hepatitis B or C 3. Administration of other investigational medicinal product within 30 days of screening 4. Ongoing toxicity > grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's "Common Terminology Criteria for Adverse Events v4.0 [CTCAE]" 5. Other ongoing severe disease that may influence the patient's ability to participate in the study 6. Pregnant or breast-feeding |
结果
主要结果指标
1. PET image analysis: Standardized Uptake Value (SUV) and uptake kinetics of [68Ga]ABY-025 in breast cancer lesions and normal tissues [Day 0]
次要成果指标
1. SUV in metastases where biopsy results with HER2 status by IHC/FISH are available [Day 0]
2. SUV for each measured lesion, and appearance or disappearance of lesions, after progression or 9-12 months therapy [Up to 1 year]
3. SUV for each measured lesion and number of detectable lesions, obtained with a low (100 μg) or high (500 μg) injected amount of ABY-025 peptide in the same subject [Day 0 & 1-3 weeks]
4. SUVs for all measured lesions obtained with a low (100 μg) or high (500 μg) injected where biopsy results with HER2 status by IHC and FISH are available [Day 0]
5. Incidence and severity of adverse events [Day 0 to 42]
6. Anti-Drug Antibody assay at 3 and 6 weeks [Day 0 to 42]
7. Blood radioactivity kinetics and dosimetry of [68Ga]ABY-025 [Day 0]
8. Uptake of [68Ga]ABY-025 coinciding with metastatic lesions visible on [18F]FDG PET and focal uptake in regions without pathological findings on [18F]FDG PET [Day 0]
